title: Drug combos validated in BRAF-mutant melanoma.
abstract: Studies presented or published during the European Society for Medical Oncology conference demonstrate that combining BRAF and MEK inhibitors improves progression-free and overall survival--and lowers the risk of resistance and toxicities--in patients with metastatic melanoma with BRAF V600E or V600K mutations.
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D048493:Proto-Oncogene Proteins B-raf